<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01963429</url>
  </required_header>
  <id_info>
    <org_study_id>NCCCTS 13-695</org_study_id>
    <nct_id>NCT01963429</nct_id>
  </id_info>
  <brief_title>Comparison Between Radiofrequency Ablation and Hypofractionated Proton Beam Radiation for Recurrent/Residual HCC</brief_title>
  <official_title>A Randomized Phase III Study of the Comparison Between Radiofrequency Ablation and Hypofractionated Proton Beam Radiation in Patients With Recurrent/Residual Small Hepatocellular Carcinoma (APROH Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Center, Korea</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Center, Korea</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase 3 study is to evaluate the effectiveness of the comparison between radiofrequency&#xD;
      ablation and hypofractionated proton beam radiation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The sample size for this study was based on a non-inferiority design. Primary objective:&#xD;
      estimate local progression-free survival (LPFS) rate in two treatments Primary endpoint:&#xD;
      2-year LPFS rate Expected 2-year LPFS rate in the RFA: 85% Accural time and follow up time:&#xD;
      24 months and 24 months, respectively. Precision for 2-year LPFS rate estimation: Allowing a&#xD;
      difference of 15% as the non-inferiority margin, with a power of 80% and a type I error level&#xD;
      of 5%, evaluable 68 patients are required.&#xD;
&#xD;
      Considering 5% of follow-up loss, we need 72 patients in each arm, so a total of 144 patients&#xD;
      will be enrolled.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 30, 2013</start_date>
  <completion_date type="Actual">January 20, 2020</completion_date>
  <primary_completion_date type="Actual">January 20, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>local progression-free survival(LPES)</measure>
    <time_frame>up to 2 year</time_frame>
    <description>To evaluate the local progression-free survival for 2 years</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>disease-free survival (DFS)</measure>
    <time_frame>up to 2 years until study closed</time_frame>
    <description>Disease-free survival was defined as the interval from the date of randomization to date of detection study closed</description>
  </secondary_outcome>
  <other_outcome>
    <measure>overall survival (OS)</measure>
    <time_frame>up to 2 years until study closed</time_frame>
    <description>Overall survival(OS) was defined as the interval from the date of randomization to date of detection study closed</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">144</enrollment>
  <condition>Recurrent Small Hepatocellular Carcinoma</condition>
  <condition>Residual Small Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>A(radiofrequency ablation )</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>radiofrequency ablation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B(Proton)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>hypofractionated proton beam therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>radiofrequency ablation</intervention_name>
    <description>* RFA(radiofrequency ablation )&#xD;
RFA electrode: Cool-tip RF ablation system (Covidien plc, 20 Lower Hatch Street Dublin 2, Ireland) and Well-Point RF Electrode (STARmed, Koea)&#xD;
performed using either the manufacturer's standard algorithm or an interactive algorithm, with the latter being used when the impedance did not begin to increase at the midinterval of the standard algorithm&#xD;
the duration of a single RFA session was 10 min to 15 min.</description>
    <arm_group_label>A(radiofrequency ablation )</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Proton beam therapy</intervention_name>
    <description>* Proton&#xD;
66 GyE /10 fx, 6.6 GyE fraction dose, 5 days/week, for HCC free from the alimentary tract (i.e., stomach, duodenum, esophagus, small and large bowel) (more than 2cm from clinical target volume),TLV30&lt;40%,and/orRLV30&lt;30%)</description>
    <arm_group_label>B(Proton)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  HCC diagnosed as (i) the presence of risk factors including hepatitis B or C virus and&#xD;
             liver cirrhosis, a serum a-fetoprotein (AFP) level greater than 200 IU/ml and a&#xD;
             radiologically compatible feature with HCC in one or more CT/MRI/angiograms, or (ii)&#xD;
             the presence of risk factors including hepatitis B or C virus and liver cirrhosis, a&#xD;
             serum a-fetoprotein (AFP) level less than 200 IU/ml, and a radiologically compatible&#xD;
             feature with HCC in two or more CT/MRI/angiograms or (iii) histological confirmation&#xD;
&#xD;
          -  HCC patients who had recurrent or residual tumor after other treatments&#xD;
&#xD;
          -  without evidence of extrahepatic metastasis&#xD;
&#xD;
          -  the largest diameter of tumor should be less than 3cm, and the number of tumor ≤2&#xD;
&#xD;
          -  no previous treatment to target tumors by other forms of RT&#xD;
&#xD;
          -  liver function of Child-Pugh class A or B7 (Child-Pugh score of ≤7)&#xD;
&#xD;
          -  Age of ≥18 years&#xD;
&#xD;
          -  performance status of 0 to 2 on the Eastern Cooperative Oncology Group (ECOG) score&#xD;
&#xD;
          -  WBC count ≥ 2,000/mm3; hemoglobin level ≥ 7.5 g/dL; platelet count ≥ 50,000/mm3; and&#xD;
             adequate hepatic function (total bilirubin ≤ 3.0 mg/dL; AST and ALT &lt; 5.0× upper limit&#xD;
             of normal; no ascites)&#xD;
&#xD;
          -  no serious comorbidities other than liver cirrhosis&#xD;
&#xD;
          -  written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  evidence of extrahepatic metastasis&#xD;
&#xD;
          -  age &lt; 18 years&#xD;
&#xD;
          -  liver function of Child-Pugh class B8-9 and C (Child-Pugh score of &gt;7) or uncontrolled&#xD;
             cases of active chronic hepatitis B&#xD;
&#xD;
          -  previous history of other forms of RT adjacent to target tumors&#xD;
&#xD;
          -  poor performance status of 3 to 4 on the Eastern Cooperative Oncology Group (ECOG)&#xD;
             score&#xD;
&#xD;
          -  pregnant or breast feeding status&#xD;
&#xD;
          -  previous history uncontrolled other malignancies within 2 years&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joong Won Park, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Center, Korea</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Cancer Center, Korea</name>
      <address>
        <city>Goyang-si</city>
        <state>Gyeonggi-do</state>
        <zip>410-769</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 13, 2013</study_first_submitted>
  <study_first_submitted_qc>October 15, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 16, 2013</study_first_posted>
  <last_update_submitted>October 4, 2020</last_update_submitted>
  <last_update_submitted_qc>October 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Cancer Center, Korea</investigator_affiliation>
    <investigator_full_name>Joong-Won Park</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>hepatocellular</keyword>
  <keyword>Proton</keyword>
  <keyword>RFA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

